Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dABE8e is a nickase-deficient adenine base editor (ABE) derived from the ABE8e system. It is engineered to perform precise adenine-to-guanine (A-to-G) transitions in genomic DNA without inducing the double-strand breaks or significant insertions/deletions (InDels) typically associated with standard CRISPR-Cas9 or nickase-active base editors. In the context of hemoglobinopathies, dABE8e is utilized to edit transcription factor binding sites within the HBG1 and HBG2 promoters (such as the -175 TAL1 site or -123/-124 KLF1 site) to induce fetal hemoglobin (HbF) production. By using a nickase-deficient architecture, dABE8e minimizes large deletions and unintended genomic modifications, making it a potentially safer tool for the treatment of sickle cell disease and β-thalassemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dabe8e.